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Abstract
Background: The purpose of this study was to characterize specific cytotoxic T-cell (CTL) responses in men who
have sex with men (MSM) subjects infected with the human immunodeficiency virus type 1 (HIV-1) CRF01_AE
subtype during the first year of infection and impacts on viral control and evolution.
Results: Fifteen HIV-1 primary infected cases were recruited from Liaoning MSM prospective cohort. CTL responses
to Gag, Pol and Nef proteins at 3 month and 1 year post infection were detected with Gamma interferon enzyme-
linked immunospot (ELISPOT) assay using optimized consensus overlapping peptides, as well as the viral
quasispecies sequences from the synchronous plasma. Gag and Nef proteins were the main targets of CTL
responses during the first year of HIV-1 infection, and this was evident from the data after adjusting for the length
of amino acids by dividing the amino acids number of the corresponding protein and multiplying by 100.
Additionally, relative magnitudes of Gag at both 3 months and 1 year post infection were significantly negatively
correlated with the viral set point (p = 0.002, r = −0.726; p = 0.025, r = −0.574). While the relative magnitude of Nef at
1 year post infection were significantly positively correlated with viral set point (p = 0.004, r = 0.697). Subjects with
multi-layered Gag immunodominant responses during the first year of infection had significantly lower viral set
points than subjects without such responses (p = 0.002).
Conclusion: Multi-layered Gag immunodominant responses during the first year of infection were correlated with viral
control, which provides a theoretical basis for vaccine design targeting MSM subjects with the CRF01_AE subtype.
Keywords: HIV-1, CTL, CRF01_AE, Gag, Immunodominant
Abbreviations: CTL, Cytotoxic T-cell; ELISPOT, Enzyme-linked immunospot; HIV-1, Human immunodeficiency virus type
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Background
Acute human immunodeficiency virus type 1 (HIV-1)
specific cytotoxic T-cell (CTL) responses play a pivotal
role in controlling viral infection [1, 2]. The first appear-
ance of CTL response coincides with [3, 4] and makes a
contribution to the decline of peak viremia in acute in-
fection [5, 6]. Acute CTL response is a critical determin-
ant of the viral set point [7–9], which has been proven
to be a strong predictor of the rate of disease progres-
sion [10]. Under the pressure of CTL response, HIV mu-
tates to escape from recognition [6, 11]. Escape
mutation may revert to the wild type upon viral trans-
mission into a human leukocyte antigen (HLA) mis-
matched individual [12]. Although compelling evidence
suggests that HIV-1-specific CD8+ T-cells play an im-
portant role in viral control, antiviral efficacy is hetero-
geneous. First, CTLs have different antiviral effectiveness
when they target different viral proteins [13–16]. Many
studies have shown that targeting the Gag protein, but
not the Env or Nef proteins, is associated with improved
disease control [17, 18]. Second, certain HLA types are
associated with different outcomes of HIV infection [19,
20]. For example, expression of HLA-*B57, B*5801 and
B*27 is associated with successful HIV control [12, 17].
In contrast, expression of HLA-B*5802 and B*3502/03 is
associated with failure to control HIV [20, 21]. These
HLA associations suggest that the specificity of HLA-
restricted CTL responses is linked to the rate of disease
progression. Third, the characteristics and effectiveness
of CTL responses may be discordant among populations
with different HLA distributions and viral subtypes [22,
23]. For example, CTL responses restricted by HLA-
B*1503, which was shown to be rare in a B subtype co-
hort but common in a C subtype cohort, were associated
with a lower viral load in the B subtype cohort. However,
such responses were not associated with a lower viral
load in the C subtype cohort [22].
HIV-1-specific CTL responses present clear immuno-
dominance patterns during early HIV-1 infection, with a
small number of epitopes being targeted in a distinct
hierarchical order [6, 11, 24–26]. The immunodomi-
nance patterns of T-cell responses are determined by
multiple factors, including kinetics of viral protein ex-
pression, virus sequence, HLA distribution, binding avid-
ity of peptides to the HLA molecule and T-cell receptor
repertoire [27, 28]. Immunodominant responses can be
defined as common reactive epitopes targeted by indi-
viduals with a specific HLA distribution at the popula-
tion level [26, 29] and the strongest response in a
subject who has developed more than one varying re-
sponse, which can be highly variable in different subjects
and may change over time largely due to HIV-1 se-
quence variation [6, 11]. Immunodominance at the
population level has been widely investigated. Studies
have previously identified several immunodominant re-
sponses as being associated with improved HIV control
[9, 26]. Immunodominance at the individual level was
found to be a major determinant of epitope escape [11],
although information regarding the relationship between
immunodominant responses at the individual level and
virus control are lacking [6, 11, 30].
In China, the number of people living with HIV has
increased in recent years [31], and the incidence of
transmission through men who have sex with men
(MSM) has shown a marked uptrend, increasing from
2.5% in 2006 to 25.8% in 2014 [31]. CRF01_AE has be-
come the predominant genotype among MSM in China
[32–34]. Two CRF01_AE lineages have been identified
in this population, with cluster I spread widely across
China and cluster II observed mainly as an epidemic in
northern China [32]. By far, the information on early
CTL responses regarding the CRF01_AE subtype in
Chinese MSM subjects is limited. Data from CTL stud-
ies in early infection have primarily been acquired from
Caucasian or African populations infected with B or C
subtype viruses [6, 17, 26]. The HLA distributions
among Caucasian and African populations differed from
Chinese populations [35], thus, it is urgent to clarify the
characteristics of CTL responses and their relationship
with virus control.
In this study, we aimed to elucidate the characteristics
of CTL responses to CRF01_AE subtype virus during
the early stage of infection and explore the protective
CTL responses correlative with viral control. We de-
signed a set of overlapping peptides to HIV-1 Gag, Pol
and Nef proteins based on the previously identified
CRF01_AE cluster II consensus sequence [32]. The CTL
responses at 3 months and 1 year post infection were
detected longitudinal with 15 primary CRF01_AE cluster
II HIV-1 infected MSM subjects. The viral quasispecies




In this study, 15 subjects with the CRF01_AE subtype
cluster II of primary HIV-1 infection were recruited
from a large-scale, high risk MSM cohort in Liaoning,
China. Blood samples and epidemiological information
were acquired every 10 weeks. HIV antibody screening
was tested with third-generation ELISA and rapid test,
and validation was performed with western blot assay.
Antibody negative samples were tested with HIV nucleic
acid. Homosexual transmission modes were confirmed
by epidemiological investigation for all subjects. The
date of infection was estimated as 14 days prior to RNA-
positive and antibody-negative results (9 subjects) or the
middle time between the last antibody-negative test and
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the first antibody-positive test (6 subjects). The average
age of the 15 subjects was 35 ± 14 years old. Peripheral
blood mononuclear cells (PBMCs) from the 15 subjects
were separated by Ficoll-PaqueTM Plus (GE Healthcare
Bio-Sciences AB, Sweden) density gradient centrifuga-
tion and cryopreserved in liquid nitrogen. The viral set
point was defined as the average viral load (at least 3
time points) from 120 days to 1 year post infection, and
the mean viral set point of the 15 subjects was 4.24
log10copies/ml (Table 1). The CD4
+ T-cell counts of all
the subjects were more than 200 cells/μl during the first
year of infection and all the subjects were anti-retroviral
naïve during the first year of infection. The signed writ-
ten informed consents were got from all subjects for
blood collection and the following study. The First Hos-
pital of China Medical University Ethics Committee ap-
proved this study (2011–36).
CD4+ T-cell counts, viral load measurement, and HLA
typing
CD4+ T-cell counts were determined using a FACS Cali-
bur flow cytometer (Becton-Dickinson, USA). Plasma
HIV-1 RNA levels were measured with the COBAS
AmpliPrep/COBAS TaqMan HIV-1 test (Roche,
Germany). HLA typing was performed using the poly-
merase chain reaction sequence-specified primer (PCR-
SSP) method, with two-digit specificities (One Lambda,
USA).
Synthetic peptides
In order to detect the CTL responses as more as pos-
sible, a set of cluster specific 18-mer peptides with 10
overlapping amino acids spanning Gag, Pol and Nef
genes were synthesized by Sigma-Aldrich (U.S.). This
set of peptides was designed based on the consensus
sequence of 50 near full length sequences from acute
CRF01_AE cluster II infected subjects which came
from a HIV seronegative prospective MSM cohort,-
with definite laboratory and epidemiology evidences
for acute infection. A total of 209 overlapping pep-
tides (OLPs) were synthesized; screening was per-
formed using a 14 × 16 matrix design in which the
principle is to mix the Gag, Pol and Nef peptides in
the second dimension rather than the first dimension
(Additional file 1: Table S1). Peptides with any re-
sponse in a given matrix allowed identification of the
common peptide represented in the two correspond-
ing pools. The identity of each peptide was confirmed
using PBMCs from the same time point. We also syn-
thesized optimal epitopes restricted by common
HLA-I alleles (A*0201, A*11, A*24, B*13, B*27, B*40,
B*51) in the Chinese population [35] (Additional file
2: Table S2). Optimal epitopes were synthesized
according to sequences from CRF01_AE subtype
cluster II.
IFN-γ ELISPOT assay
IFN-γ enzyme-linked immunospot (ELISPOT) assays
were performed as previously described [36]. In brief,
PBMCs were plated in 96-well plates that were pre-
coated with anti-IFN-γ monoclonal antibody at 100,000
cells per well with peptides at a final concentration of 5
μg/ml for pooled peptides, single peptides, and optimal
epitopes (BDTM ELISPOT, USA). Phytohemagglutinin
(PHA) served as a positive control at a concentration of
10 μg/ml, and medium alone was the negative control.
Spots were counted using the ImmunoSpot® Analyzer
(Cellular Technology Ltd, USA), and the number of spe-
cific T-cells was counted by subtracting the mean nega-
tive control values. Responses were considered positive
if the activity was at least three times greater than the
mean number of spot-forming cells (SFCs) in the nega-
tive control as well as >50 SFCs per 106 PBMCs.
Gag sequencing
Viral RNA was extracted from plasma samples ob-
tained from MSM subjects with the QIAamp Viral
RNA Mini-kit (Qiagen, UK). The Gag gene was amp-
lified using the SuperScript Polymerase One-Step RT-
PCR System (Takara, Dalian, China), followed by a
second round of PCR with Gag-specific primers [36].
PCR products were gel purified with the QIAquick
gel extraction kit (Qiagen, UK) and cloned with a








Subject 1 CRF01_AE 671 2.84 01,33 07,35 07,12
Subject 2 CRF01_AE 507 2.95 02,29 27,40 02,03
Subject 3 CRF01_AE 578 3.53 03,24 15,49 07,08
Subject 4 CRF01_AE 657 3.58 02,24 13,40 03,08
Subject 5 CRF01_AE 670 3.75 02,32 13,44 03,04
Subject 6 CRF01_AE 557 4.29 01,02 15,57 06,06
Subject 7 CRF01_AE 498 4.30 02,26 38,48 08,12
Subject 8 CRF01_AE 407 4.43 02,11 13,13 02,03
Subject 9 CRF01_AE 614 4.49 02,80 15,15 03,03
Subject 10 CRF01_AE 416 4.50 02,30 13,46 01,06
Subject 11 CRF01_AE 254 4.61 02,02 15,58 03,03
Subject 12 CRF01_AE 695 4.62 02,11 40,46 01,08
Subject 13 CRF01_AE 280 5.08 02,30 13,13 06,07
Subject 14 CRF01_AE 440 5.20 02,11 15,40 03,07
Subject 15 CRF01_AE 664 5.38 11,11 35,54 01,01
aSubtypes were all CRF01_AE cluster II
bMedian CD4 counts were calculated from at least 3 time points from 3
months to 1 year post infection
cSet point was the average viral load from 120 days to 1 year post infection
(at least 3 time points)
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TOPO TA cloning kit (Invitrogen, USA). The cloning
PCR fragments were then sequenced with Sanger se-
quencing method using ABI 3730 DNA analyzer by
Huada Genomics Company (China). A sequencer pro-
gram was used to assemble and edit individual se-
quence fragments.
Statistical analysis
Data analysis and graphical presentation were performed
with IBM SPSS version 20.0 software and GraphPad
Prism version 5.0 software. Statistical analysis of signifi-
cance was performed using either the Wilcoxon signed-
rank test or Friedmen’s two-way analysis of variance by
ranks followed by pairwise multiple comparisons for
comparing characteristics of HIV-1-specific CTL re-
sponses and using the Mann-Whitney test for compar-
ing the viral set points between different groups.
Spearman rank correlation was used to assess relation-
ships between viral set points and HIV-specific T-cell re-
sponses. A p value less than 0.05 was considered
statistically significant.
Results
Characteristics of HIV-1-specific CTL responses during the
first year of infection
To clarify the characteristics of CTL responses during
the first year of infection, Gag-, Pol- and Nef-specific
CTL responses were evaluated longitudinally in 15 MSM
subjects with the HIV-1 CRF01_AE subtype at 3 months
and 1 year post infection. There were no significant dif-
ferences at either time point among Gag-, Pol- and Nef-
specific CTL responses in terms of magnitude and
breadth (p > 0.05). The magnitude and breadth of Gag,
Pol and Nef responses increased over time, with signifi-
cant differences in the magnitude of Gag and Pol (p <
0.05 for both) and breadth of Pol and Nef (p < 0.05 for
both) (Fig. 1a, b).
We adjusted for the length of amino acids by dividing
the amino acids number of the corresponding protein
and multiplying by 100, and found that Gag and Nef re-
sponses were the mainly targets during the first year of
infection. The adjusted breadth of Gag was significantly
broader than that of Pol at 1 year post infection (p <
0.05, Fig. 1d). Similarly, the adjusted breadth of Nef was
significantly broader than that of Pol at 3 months and 1
year post infection (p < 0.05 and p < 0.001, respectively,
Fig. 1d). In addition, the adjusted magnitude of Gag and
Nef were significantly higher than that of Pol at 1 year
post infection respectively (p < 0.05 and p < 0.01, respect-
ively, Fig. 1c). There were no significant differences
among Gag, Pol and Nef in adjusted magnitude at 3
months post infection. Different protein regions present-
ing different T-cell responses may be associated with
variations in viral control.
Fig. 1 Characteristics of HIV-specific CTL responses at 3 months and 1 year post infection. The magnitude (a) and breadth (b) of Gag-, Pol- and
Nef-specific CTL responses at 3 months and 1 year post infection. Adjusted magnitude (c) and adjusted breadth (d) of Gag-, Pol- and Nef-specific
CTL responses at 3 months and 1 year post infection. Adjusted magnitude and adjusted breadth were calculated by dividing the amino acids
number of the corresponding protein and multiplying by 100. Circles depict Gag-, Pol- and Nef-specific CTL responses and adjusted responses at
3 months post infection; triangles depict Gag-, Pol- and Nef-specific CTL responses and adjusted responses at 1 year post infection. * p < 0.05, **
p < 0.01, *** p < 0.001
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Relative magnitude of Gag-specific responses showed a
significantly inverse association with viral set point during
the first year of infection
To clarify the relationship between CTL responses and
viral control in the CRF01_AE subtype, we analyzed the
effects of magnitude and breadth of Gag-, Pol- and Nef-
specific CTL responses at 3 months and 1 year post in-
fection on viral set point. Neither magnitude nor breadth
of Gag-, Pol- or Nef-specific responses were correlated
with viral set point during the first year of infection (p >
0.05, Fig. 2a–f and Additional file 3: Figure S1a–S1f ), al-
though the magnitude of Nef at 1 year post infection
was significantly positively correlated with viral set point
(p = 0.01, r = 0.642, Fig. 2f ).
Several studies have suggested that relative magnitude
and breadth, which were defined in this study as the
proportion of magnitude and number of reactive pep-
tides in a specific protein to the total virus-specific
magnitude and the total number of recognized peptides,
respectively, are more sensitive markers of viral control
than magnitude and breadth [16, 37]. Thus, we further
analyzed the effect of relative magnitude and relative
breadth of Gag-, Pol- and Nef-specific CTL responses
on viral set point during the first year of infection. We
observed a significantly negative correlation between the
relative magnitude of Gag and viral set point at 3
months (p = 0.002, r = −0.726, Fig. 2g) and 1 year (p =
0.025, r = −0.574, Fig. 2j) post infection. However, no
correlation was observed between the relative magnitude
of Pol-specific responses and viral set point during the
first year of infection (p > 0.05, Fig. 2h–k). In contrast,
the relative magnitude of Nef at 1 year post infection
was significantly positively correlated with viral set point
(p = 0.004, r = 0.697, Fig. 2l). In addition, no correlation
was observed between the relative breadth of Gag-, Pol-
and Nef-specific responses and viral set point at 3
Magnitude of responses (SFU/106 PBMC)




















Fig. 2 Association between viral set point and HIV-1-specific CD8+ T-cell responses. (a–c) Spearman correlation between magnitude of HIV-1-specific
responses and set point at 3 months post infection; a Gag, b Pol, c Nef. d–f Spearman correlation between the magnitude of HIV-1-specific responses
and set point at 1 year post infection; d Gag, e Pol, f Nef. g–i Spearman correlation between relative magnitude of HIV-1-specific responses and set
point at 3 months post infection; g Gag, h Pol, i Nef. j–l Spearman correlation between relative magnitude of HIV-1-specific responses and set point at
1 year post infection; j Gag, k Pol, l Nef. Relative magnitude was defined in this study as the proportion of magnitude in a specific protein to the total
virus-specific magnitude
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months or 1 year post infection (Additional file 3: Figure
S1g-S1l). This suggests that the higher relative magni-
tude of Gag presented during the first year of infection
leads to improved viral control.
Multi-layered Gag immunodominant responses were
correlated with viral control during the first year of
infection
A higher relative magnitude of Gag is likely associated
with improved viral control, indicating an immunodomi-
nant response, which is defined as one of the strongest
responses for each subject at each time point in this
study, targeting the Gag protein may also be related to
better viral control. We analyzed the relationship
between immunodominant response and viral set point
for each subject to clarify the effect of Gag immunodo-
minant response on viral control. Different subjects pos-
sessed shifting immunodominance hierarchies over time
due to interactions between host and virus. Based on dif-
ferent characteristics of immunodominance and viral set
point, we classified the 15 subjects into 3 groups. Group
1 was characterized by having multi-layered immunodo-
minant responses targeting Gag during the first year of
infection, which was defined as having Gag immunodo-
minant responses targeting the same epitope or different
epitopes at both 3 month and 1 year post infection to
force persistent immune pressure on virus. 5 subjects
belonging to group 1 showed lower viral set points, ran-
ging from 2.84 to 3.75 log10copies/ml. Of the 5 subjects,
subject 2 had an immunodominant response targeting
the KK10 epitope restricted by HLA-B27 at 3 months
and 1 year post infection. However, the other 4 subjects
(subject 1, 3, 4 and 5) had immunodominant responses
targeting different Gag epitopes at 3 months. The immu-
nodominance hierarchies subsequently shifted over time,
and the subjects developed another layer of immunodo-
minant responses targeting new Gag epitopes at later
stages of infection (Fig. 3a–e). Group 2 was character-
ized by having immunodominant responses targeting
different proteins during the first year of infection, the
viral set points of the 6 subjects belonging to group 2
ranged from 4.29 to 4.62 log10copies/ml. Of the 6 sub-
jects, subject 12 had Gag immunodominant responses at
3 months, but not at 1 year post infection (Fig. 3f ). Sub-
ject 6, 9 and 11 had Pol immunodominant responses at
3 months post infection, and subject 11 had a persistent
Pol immunodominant response during the first year of
infection (Fig. 3g–i). Subject 7 and 10 had Nef immuno-
dominant responses at 3 months, but not at 1 year post
infection (Fig. 3j, k). Group 3 was characterized by hav-
ing persistent immunodominant responses targeting Nef
during the first year of infection, 4 subjects belonging to
Fig. 3 HIV-1-specific CTL kinetics in different subjects. a Subject 2, b Subject 1, c Subject 3, d Subject 4, e Subject 5, f Subject 12, g Subject 6, h
Subject 9, i Subject 11, j Subject 7, k Subject 10, l Subject 8, m Subject 13, n Subject 14, o Subject 15. HIV-1-specific CD8+ T-cell against 18 mer
overlapping peptides and optimal epitopes are shown as solid lines. Viral loads are shown as dotted lines. Epitopes containing OLPs (overlapping
peptides) indicates that it was an 18 mer overlapping peptide, and containing HLA type indicates that it was an optimal epitope restricted by a
certain HLA type. Position and sequence of the optimal epitopes see Additional file 2: Table S2. Colored lines represent different protein responses
in each subject. Red, green and yellow lines represent Gag, Pol and Nef responses, respectively
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group 3 showed the highest viral set points among these
three groups, ranging from 4.43 to 5.38 log10copies/ml
(Fig. 3l–o). None of the subjects in group 2 nor group 3
had multi-layered immunodominant responses targeting
Gag during the first year of infection.
We further compared the viral set points from differ-
ent subjects according to Gag immunodominance and
found that the viral set point in group 1 was significantly
lower than in group 2 and group 3 (3.33 log10copies/ml
VS 4.69 log10copies/ml, p = 0.002), meaning that the viral
set points in subjects who had multi-layered immunodo-
minant responses targeting Gag were significantly lower
than in subjects without the same response during the
first year of infection. This suggests that multi-layered
immunodominant responses targeting Gag during the
first year of infection were correlated with viral control.
Gag immunodominant responses exerted pressure on the
virus during early infection
The observation that multi-layered Gag-specific immu-
nodominant responses during the first year of infection
were correlated with viral control suggested that Gag
immunodominant responses may exert strong immune
pressure on the virus. To study epitope mutation under
the pressure of Gag immunodominant responses, we an-
alyzed Gag cloning sequences during the first year of in-
fection. Epitope and flanking region mutations were
defined as amino acid mutations with a ≥50 % change in
cloning sequences at 1 year compared to the cloning se-
quences at 3 months. We observed a large proportion of
mutated Gag immunodominant epitopes and their flank-
ing regions over time. The AV9 epitope in subject 4 and
the IL10 epitope in subject 12 had mutations at 1 year
post infection. In addition, the GI11 epitope in subject 5
had flanking region mutations at 1 year post infection.
OLP-45 in subject 1 and OLP-10 in subject 3 had flank-
ing region mutations at 1 year post infection based on
putative epitopes within the 2 overlapping peptides.
Only the KK10 epitope in subject 2 had no mutations
and maintained an immunodominant response at 1 year
post infection (Table 2). Epitope and flanking region mu-
tations could hamper CTL responses [6, 38]. With epi-
tope and flanking region mutations, the magnitude of
AV9, GI11, OLP-45 and IL10 epitopes were all reduced
at 1 year post infection, and only OLP-10 in subject 3
was slightly increased (Fig. 3). Under CTL pressure, 5
out of 6 Gag immunodominant epitopes or their flank-
ing regions mutated over time, suggesting that Gag
immunodominant responses at 3 months exerted strong
pressure on the virus.
Discussion
Evidence has suggested that early CTL responses to
HIV-1 infection are vital to viral control [8, 39].
Therefore, a comprehensive understanding of effective
CTL response parameters during early infection are im-
portant for vaccine design and therapeutic strategy [2].
Through longitudinal analysis of 15 Chinese MSM sub-
jects infected with the CRF01_AE subtype, which is
dominant among Chinese MSM subjects and has shown
a dramatic uptrend in recent years [32–34], we clarified
the characteristics of early CTL responses in CRF01_AE
using unique cluster-specific peptides and found that
multi-layered immunodominant responses targeting Gag
during the first year of infection were significantly asso-
ciated with improved viral control. This information is
useful in vaccine design targeting Chinese MSM subjects
infected with the CRF01_AE subtype.
In this study, Gag and Nef proteins were the main tar-
gets of CTL responses during the first year of HIV-1 in-
fection, and this was evident from the data after
adjusting for the length of amino acids by dividing the
amino acids number of the corresponding protein and
multiplying by 100 (Fig. 1). These results were similar to
the cohort study regarding the B subtype in Streeck et
al. [40], although differed from the cohort study in the C
subtype in Radebe et al. [41] in which the breadth of Pol
was broader at 3 months post infection. This discord-
ance may be due to differences in viral subtype and
HLA distribution.
It was generally believed that the viral set point was
established about 4 months post infection [42]. CTL re-
sponses at 3 months post infection were detected to find
host response contribute to viral set point. Moreover,
CTL responses at 1 year post infection were also de-
tected to illustrate the CTL responses dynamics.
Through correlation analysis between CTL responses
and viral set points, we found that the relative magni-
tude of Gag was significantly negatively correlated with
viral set point in CRF01_AE during the first year of in-
fection (Fig. 2), suggesting that the higher proportion of
Gag magnitude was associated with improved viral con-
trol. This is similar to the results presented in Masemola
et al. [16] and Zuniga et al. [37]. Through longitudinal
analysis of Gag immunodominant responses and viral
set points in each subject, we found that multi-layered
immunodominant responses targeting Gag during the
first year of infection were correlated with viral control
(Fig. 3). In addition, we noticed that subject 12, who had
a relatively high viral set point (4.62 log10 copies/ml),
had a Gag immunodominant response at 3 months.
Under host immune pressure, the immunodominant epi-
tope mutated and magnitude was decreased at 1 year
post infection. However, no immunodominant responses
targeting Gag developed during later stages of infection
(Fig. 3f and Table 2), suggesting that only having an
immunodominant Gag response in early infection is not
sufficient to control the virus. Two other subjects
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(subject 9 and 10) with relatively high viral set points
(4.49 and 4.50 log10copies/ml, respectively) only had Gag
immunodominant responses at 1 year post infection,
which suggests that developing Gag immunodominant
responses in early stages of infection is important for
viral control (Fig. 3h, k). These data suggest that multi-
Table 2 Longitudinal sequence analysis of Gag immunodominant epitopes at 3 months post infection
a HLA types in parentheses denote the putative restricting HLA. Underlined sections denote putative epitopes
bDominant time indicates that the epitope had an immunodominant response at a specific time point
cAmino acids in the dashed boxes denote mutation sites. 3M = 3 months, 1Y = 1 year
dTo specify the flanking region mutation in the GI11 epitope in subject 5, we only show the N terminal amino acid sequence
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layered defenses during the first year of infection are
needed to effectively control the virus. Tulk et al. found
that Gag immunodominance during early infection was
correlated with increased plasma IL-2 and MIP-β levels
[14], which are associated with better disease control
[43, 44]. This may provide one of the reasons why multi-
layered Gag immunodominant responses during the first
year of infection were correlated with viral control.
We observed that both the magnitude and relative
magnitude of Nef responses at 1 year post infection were
significantly positively correlated with viral set point
(Fig. 2), which was similar to results from Kiepiela et al.
[13]. We also found that the viral set points in 4 subjects
(subject 8, 13, 14 and 15) who had persistent immuno-
dominant responses targeting Nef were high (Fig. 3),
which was consistent with the study of Radebe et al.
[45], suggesting that these responses targeting Nef pro-
tein are driven by the level of viremia, rather than being
responsible for lowering viral load.
Through longitudinal analysis of Gag cloning sequences
during the first year of infection, we found that Gag
immunodominant responses at 3 months may exert
strong pressure on the virus. Five out of 6 Gag immuno-
dominant epitopes or their flanking regions had mutations
at 1 year post infection (Table 2). Moreover, the magni-
tude of the 5 epitopes with mutations within epitopes or
their flanking regions all decreased over time, except for
the OLP-10 peptide in subject 3 in which the magnitude
slightly increased (Fig. 3 and Table 2). Although we did
not validate mutated immunodominant epitopes at 1 year
post infection, the decline in magnitude suggests that epi-
tope and flanking region mutations could hinder CTL re-
sponses [6, 38]. Only the B27 restricted KK10 epitope in
subject 2 had no mutations and still maintained an immu-
nodominant response at 1 year post infection (Fig. 3 and
Table 2). Many studies have shown that targeting the
KK10 epitope could effectively control the virus [17], be-
cause escape mutations in the KK10 epitope could confer
a large fitness cost to the virus. Escape mutations did not
occur until the development of compensatory mutations
restored viral replication in chronic infection [17]. This re-
sult was similar to the Liu et al. [11] study, which reported
that immunodominant responses within an individual
were a key reason for escape mutations. These data sug-
gest that Gag immunodominant responses at 3 months
exert strong pressure on the virus, which drives the virus
to mutate and escape immune pressure. Several subjects
(subject 1, 3, 4 and 5) with improved viral control gained
another layer of defense, developing new Gag immunodo-
minant responses at later stages of infection and forcing
persistent strong immune pressure on the virus, thereby
indicating that multi-layered Gag-specific immunodomi-
nant responses during the first year of infection may con-
tribute to better viral control.
In this study, we aimed to explore the protective CTL
responses to CRF01_AE correlative with viral control,
which were suitable for vaccine design and immunother-
apy among Chinese MSM subjects, so the published op-
timal epitopes restricted by the most common HLA-I
alleles in the Chinese population were also selected and
tested [35]. Some responses might be missed, but the
conclusion was believed not to be affected, because most
of the known protective epitopes were located in Gag,
Pol and Nef proteins [46], which had been screened with
the CRF01_AE cluster II specific overlapping peptides.
Additionally, only CRF01_AE cluster II HIV-1 infected
cases were included in this study, since predominant
proportion (81.3 %) of MSM subjects infected HIV-1
strains belonged to CRF01_AE cluster II in this Liaoning
MSM prospective cohort [32]. However, whether the re-
sults of this study were also appropriate for CRF01_AE
cluster I infected cases need further validation.
Conclusions
Through longitudinal analysis of CTL responses and Gag
cloning sequences from 15 MSM subjects with the
CRF01_AE primary infection, we found that multi-layered
immunodominant responses targeting Gag during the first
year of infection were correlated with viral control. We
speculate that combined selection of multiple Gag immu-
nodominant epitopes as candidate immunogens at early
stages of infection may force a multi-layered defense on
HIV-1 in order to achieve better viral control. These data
provide a theoretical basis for vaccine design targeting the
CRF01_AE subtype in MSM subjects.
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